Replimune Group (NASDAQ:REPL) Sets New 1-Year High – Should You Buy?

Replimune Group, Inc. (NASDAQ:REPL)’s share price hit a new 52-week high on Tuesday. The company traded as high as $21.26 and last traded at $20.2010, with a volume of 705,865 shares changing hands. The stock had previously closed at $19.49.

Analyst Upgrades and Downgrades

REPL has been the subject of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. Wolfe Research raised Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. Leerink Partners increased their price objective on Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a research report on Thursday, October 29th. Weiss Ratings cut Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Finally, Piper Sandler upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $14.33.

Replimune Group Trading Up 4.1%

The company has a fifty day simple moving average of $13.67 and a two-hundred day simple moving average of $9.40. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 1.00. The stock has a market capitalization of $1.90 billion, a P/E ratio of -7.32 and a beta of 0.93.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.24. On average, sell-side analysts expect that Replimune Group, Inc. will post -2.61 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Emily Hill sold 11,448 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,480.56. Following the sale, the chief financial officer owned 225,108 shares in the company, valued at approximately $2,919,650.76. This represents a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $148,467.59. Following the transaction, the insider directly owned 224,215 shares of the company’s stock, valued at $2,908,068.55. This trade represents a 4.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 79,124 shares of company stock worth $1,038,364 over the last 90 days. 5.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. AXQ Capital LP boosted its holdings in shares of Replimune Group by 4.1% in the 2nd quarter. AXQ Capital LP now owns 27,121 shares of the company’s stock valued at $300,000 after buying an additional 1,056 shares during the last quarter. Walleye Capital LLC grew its stake in shares of Replimune Group by 3.2% in the first quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock valued at $548,000 after buying an additional 2,192 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Replimune Group by 30.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 17,191 shares of the company’s stock valued at $223,000 after buying an additional 4,050 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Replimune Group during the third quarter worth $64,000. Finally, Allworth Financial LP acquired a new position in Replimune Group during the second quarter worth $62,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.